Mereo BioPharma Inc. (NASDAQ: MREO) stock declined by 3.11% at the last close, whereas the MREO stock price surges by 6.42% in the pre-market trading session. Mereo BioPharma is a pharmaceutical firm dedicated to the research, development, and marketing of novel medicines for cancer and rare illnesses.
MREO stock’ Recent Past Development
Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE), and the Osteogenesis Imperfecta Foundation (OIF) have announced that participation in the biggest worldwide data collection on the effect of OI on persons with OI, their families, and caretakers is now complete. The IMPACT Survey received approximately 2200 individual answers from 65 countries over the course of three months. The survey data will assist future joint efforts aimed at improving OI diagnosis, treatment, and care, as well as the prompt assessment and availability of possible novel therapies. The preliminary findings will be released in 2022.
OI is a rare genetic disease characterized by a collagen deficiency that causes brittle bones and low bone mass, resulting in easily broken bones. In extreme situations, individuals may suffer hundreds of fractures over the course of their lives. Muscle weakness, early hearing loss, tiredness, bent bones, scoliosis, respiratory and digestive difficulties, and low height are common in persons with OI, all of which have a major influence on overall health and quality of life. Despite its severity, the full impact of OI on persons with the disease, their families, and carers is little known and recorded. This is identical to many rare disorders, especially ones with no authorized treatment, such as OI.
Furthermore,
The findings of a comprehensive literature review conducted by Mereo were reported at the American Society for Bone and Mineral Research (ASBMR) 2021 and are scheduled to be fully published in 2022. Mereo, Ultragenyx (partners in the creation of setrusumab for the cure of OI), and the OI community, coordinated by the umbrella organizations OIFE and OIF, collaborated closely to make the IMPACT Survey a reality.
